Predictions
Jazz Pharmaceuticals plc
Start price
Target price
Perf. (%)
€129.60
29.04.23
29.04.23
-
29.04.24
29.04.24
-19.52%
30.04.24
30.04.24
Bausch Health Companies Inc.
Start price
Target price
Perf. (%)
€9.75
07.04.24
07.04.24
€13.00
07.04.25
07.04.25
-17.28%
28.04.24
28.04.24
Could be very worthwhile Investment >20% year
Fibrogen Inc.
Start price
Target price
Perf. (%)
€1.07
19.04.24
19.04.24
-
19.04.25
19.04.25
-10.90%
28.04.24
28.04.24
Could be very worthwhile Investment >20% year
Arrowhead Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€30.42
26.04.23
26.04.23
€72.10
26.04.24
26.04.24
-32.54%
27.04.24
27.04.24
Nektar Therapeutics
Start price
Target price
Perf. (%)
€1.50
11.04.24
11.04.24
-
11.04.25
11.04.25
3.27%
14.04.24
14.04.24
Risky Investment
Emergent Biosolutions Inc.
Start price
Target price
Perf. (%)
€11.36
10.04.23
10.04.23
€20.27
10.04.24
10.04.24
-82.04%
11.04.24
11.04.24
Neurocrine Bioscience
Start price
Target price
Perf. (%)
€89.90
30.03.23
30.03.23
€120.95
30.03.24
30.03.24
47.22%
01.04.24
01.04.24
Fibrogen Inc.
Start price
Target price
Perf. (%)
€2.22
21.03.24
21.03.24
-
21.03.25
21.03.25
2.97%
29.03.24
29.03.24
Probably not worthwhile Investment
Halozyme Therapeutics Inc.
Start price
Target price
Perf. (%)
€32.24
27.03.23
27.03.23
-
27.03.24
27.03.24
16.75%
28.03.24
28.03.24
PTC Therapeutics Inc.
Start price
Target price
Perf. (%)
€41.20
25.03.23
25.03.23
-
25.03.24
25.03.24
-35.92%
26.03.24
26.03.24
Dr. Reddy's Laboratories Ltd. ADR
Start price
Target price
Perf. (%)
€52.50
17.03.23
17.03.23
-
17.03.24
17.03.24
33.33%
18.03.24
18.03.24
Sage Therapeutics Inc.
Start price
Target price
Perf. (%)
€42.33
13.03.23
13.03.23
€56.02
13.03.24
13.03.24
-56.77%
14.03.24
14.03.24
Amicus Therapeutics Inc.
Start price
Target price
Perf. (%)
€10.70
11.03.23
11.03.23
-
11.03.24
11.03.24
2.80%
12.03.24
12.03.24
Invitae Corp
Start price
Target price
Perf. (%)
€1.30
11.03.23
11.03.23
€0.40
11.03.24
11.03.24
-93.65%
12.03.24
12.03.24
Could be worthwhile Investment >10% per year
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Viatris Inc.
Start price
Target price
Perf. (%)
€9.76
18.10.22
18.10.22
-
18.11.26
18.11.26
13.97%
11.03.24
11.03.24
Probably not worthwhile Investment